CGP-74514
CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50=25 nM) . CGP-74514 inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 is promising for research of bladder cancer[1][2].
Product Specifications
CAS Number
190653-73-7
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Purity
98.02
Smiles
CCN1C=NC2=C(NC3=CC=CC(Cl)=C3)N=C(N[C@H]4[C@@H](N)CCCC4)N=C12
Molecular Formula
C19H24ClN7
Molecular Weight
385.89
References & Citations
[1]Furet P, et al. Structure-based design of potent CDK1 inhibitors derived from olomoucine. J Comput Aided Mol Des. 2000 Jul;14 (5) :403-9.|[2]Imbach P, et al. 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9 (1) :91-6.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
OR1091424-01 250 mg
(5- (tert-butyl) -2-chlorophenyl) (phenyl) methanol
Sign In for Pricing
View Details